 "Sun Pharma Q2FY25 results: Net profit rises 28% to Rs 3,040 crore")
Sun Pharmaceutical Industries on Monday reported a 28 per cent increase in its consolidated net profit to Rs 3,040 crore in the September quarter.
The drug major had posted a net profit of Rs 2,375 crore in the July-September quarter of last fiscal.
Total income rose to Rs 13,645 crore in the second quarter compared to Rs 12,486 crore in the year-ago period, the Mumbai-based drug major said in a regulatory filing.
"Sun has recently strengthened its specialty pipeline through an agreement with Philogen for commercialising late stage candidate Fibromun, upon approval," Dilip Shanghvi, Chairman and Managing Director of the company, said.
With Fibromun, the company's product basket for dermatologists has expanded further, he added.
"We shall continue to leverage our strong cash position to strengthen our pipeline with products that are close to market," Shanghvi said.
Shares of the company were trading 2.22 per cent higher at Rs 1,901.55 apiece on the BSE.
(Only the headline and picture of this report may have been reworked by the Business Standard staff; the rest of the content is auto-generated from a syndicated feed.)
You’ve reached your limit of {{free_limit}} free articles this month.
Subscribe now for unlimited access.
Already subscribed? Log in
Subscribe to read the full story →
Smart Quarterly
₹900
3 Months
₹300/Month
Smart Essential
₹2,700
1 Year
₹225/Month
Super Saver
₹3,900
2 Years
₹162/Month
Renews automatically, cancel anytime
Here’s what’s included in our digital subscription plans
Exclusive premium stories online
Over 30 premium stories daily, handpicked by our editors
Complimentary Access to The New York Times
News, Games, Cooking, Audio, Wirecutter & The Athletic
Business Standard Epaper
Digital replica of our daily newspaper — with options to read, save, and share
Curated Newsletters
Insights on markets, finance, politics, tech, and more delivered to your inbox
Market Analysis & Investment Insights
In-depth market analysis & insights with access to The Smart Investor
Archives
Repository of articles and publications dating back to 1997
Ad-free Reading
Uninterrupted reading experience with no advertisements
Seamless Access Across All Devices
Access Business Standard across devices — mobile, tablet, or PC, via web or app